Beck

Kerrigan Advisors Represents Beck & Masten Auto Group in Sale of Three High Volume Buick GMC Dealerships to Group 1 Automotive

Retrieved on: 
Friday, May 12, 2023
Professional Services, Business, Automotive, Other Professional Services, Other Automotive, Small Business, Finance, Beck, Pontiac, GMC, Group 1 Automotive, Dealer, Kerrigan, Buick, Quality of life, 186th, Sale, GPI, 185th, Blue Sky, 184th, Family, NYSE, Population growth, General Motors, Car dealership, Financial services

Kerrigan Advisors, the premier sell-side advisor and thought partner to auto dealers nationwide, represented Houston, Texas-based Beck & Masten Auto Group in the sale of Beck & Masten Buick GMC North, Buick GMC South and Buick GMC Coastal Bend to Houston, Texas-based Group 1 Automotive (NYSE: GPI).

Key Points: 
  • Kerrigan Advisors, the premier sell-side advisor and thought partner to auto dealers nationwide, represented Houston, Texas-based Beck & Masten Auto Group in the sale of Beck & Masten Buick GMC North, Buick GMC South and Buick GMC Coastal Bend to Houston, Texas-based Group 1 Automotive (NYSE: GPI).
  • The dealership was eventually relocated to Houston and is now called Beck & Masten Buick GMC North.
  • The success of Beck & Masten Buick GMC North brought about Beck & Masten Buick GMC South in 2000, which also grew into one of the top-performing domestic dealerships in Houston and Texas.
  • Notably, Beck & Masten’s three Buick GMC dealerships have an 8% market share for Buick GMC sales in Texas.

5 Point App Launches an Innovative Cancer Self-Care Application

Retrieved on: 
Wednesday, April 5, 2023
Beck, Infection, Survivor, Acupuncture, PI, Teaching, Sleep, Cancer, Quality of life, SL, Android, Acupressure, Medicine, Bangladesh Technical Education Board, IOS, National Cancer Institute, Cancer-related fatigue, Patient, Research, Health, Fatigue, Nursing, Mobile phone, Medical imaging

NEW YORK, April 5, 2023 /PRNewswire/ -- 5 Point App Inc, a company committed to improving patient health outcomes, is proud to announce the launch of its intuitive mobile health application, EnergyPoints™. The app integrates the power of technology with the ancient practice of acupressure to help cancer patients and survivors manage fatigue and sleep disturbances.

Key Points: 
  • NEW YORK, April 5, 2023 /PRNewswire/ -- 5 Point App Inc, a company committed to improving patient health outcomes, is proud to announce the launch of its intuitive mobile health application, EnergyPoints ™.
  • The app integrates the power of technology with the ancient practice of acupressure to help cancer patients and survivors manage fatigue and sleep disturbances.
  • In the US, up to 90% of cancer patients receiving treatment experience fatigue, and 30% may experience long-lasting fatigue.
  • Sleep disturbances, affecting up to 75% of cancer survivors, can also contribute to poor health and may exacerbate fatigue.

Clinical Trial of Arcade Therapeutics' Flagship Therapeutic Mobile Game, StarStarter Rx, Shows Robust Reductions in Social Anxiety in Adults

Retrieved on: 
Thursday, March 23, 2023
Arcade, Liebowitz social anxiety scale, Anxiety, Policy, COVID-19, SAD, Document Number Nine, Document, DSM-IV codes, Food and Drug Administration Amendments Act of 2007, Patient, Beck Depression Inventory, LSAS, Social anxiety disorder, Generalized anxiety disorder, Beck, FDA, Therapy, Social anxiety, Food, Safety, Nursing, Pharmaceutical industry

Arcade's clinical research uses a gold-standard placebo sham in research studies that isolates and controls for the therapy's mechanism of action.

Key Points: 
  • Arcade's clinical research uses a gold-standard placebo sham in research studies that isolates and controls for the therapy's mechanism of action.
  • "We are thrilled by these promising results as we continue down the path toward FDA submission of StarStarter Rx as the first game-based treatment for Social Anxiety Disorder."
  • StarStarter Rx is available with the Arcade Connect DTx deployment platform, which includes integration features, clinical assessments, and HIPAA-consent management.
  • StarStarter Rx is not intended for use as a standalone therapy and does not represent a substitution for your medication.

Leading Technology Company TMRW Life Sciences Adds Seasoned Executives in Mission to Raise the Standard of Care for Fertility Clinics and Patients Worldwide

Retrieved on: 
Wednesday, March 22, 2023
Beck, OvaScience, Cancer, GV (company), Emerge Commerce, NPX, IVF, Bayer, Acquisition, Patient, Standard of care, Laboratory, Fertility, Growth, Francisco de Comontes, Entrepreneurship, International expansion of Netflix, FDA, Nature photography, TMRW, Safety, Automation, Egg, Management, Nursing, GV, A.I, Conceptus

NEW YORK, March 22, 2023 /PRNewswire/ -- TMRW Life Sciences, Inc. ("TMRW"), the fast-growing fertility technology company, has announced two new executive team members. Lindsay Beck has been appointed Chief Impact Officer and Louis Villalba has been appointed Chief Business Officer. TMRW created the world's first and only FDA-cleared, automated platform for the safe management of frozen eggs and embryos, ushering in a new standard of care in the field of fertility. Beck and Villalba are each proven executives with decades of experience across multiple healthcare sectors, focused on innovation and the adoption of radically improved new ways of operating.

Key Points: 
  • "Lindsay is both a force for good and a true change-agent, inspiring entire fields within healthcare to do better for patients.
  • "She spent more than a decade fighting for cancer patients and their fertility rights, changing the standard of care and positively impacting millions of patients' lives.
  • "I am thrilled to join the brilliant TMRW team and our pioneering fertility clinic partners to raise the bar for patients again."
  • TMRW's platform has already been adopted by leading IVF clinics across the U.S. and I look forward to further extending this new standard of care globally."

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

Retrieved on: 
Tuesday, March 7, 2023
Mental, Phase, CFB, BDI, Anxiety, Depression, Beck Depression Inventory, N,N-Dimethyltryptamine, IV, Safety, Major depressive disorder, Beck, Patient, MDD, MADRS, Pharmaceutical industry, N

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces further positive results from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”). The trial investigated the efficacy and safety of a 21.5mg intravenous (“IV”) dose of SPL026, N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD. Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results.

Key Points: 
  • The trial investigated the efficacy and safety of a 21.5mg intravenous (“IV”) dose of SPL026, N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD.
  • The two-staged study included a two-week blinded, randomized, placebo-controlled phase followed by a 12-week open-label phase, in which all participants received a single dose of SPL026.
  • SPL026 with supportive therapy also demonstrated a rapid onset and durable antidepressant effect, as assessed by the Montgomery-Asberg Depression Rating Scale (“MADRS”).
  • Further analysis of the Phase IIa dataset is ongoing and full trial results will be submitted for publication in a peer-reviewed journal.

EQS-News: ID Finance Investments, S.L.: ID Finance closes 2022 with a record revenue of €170M 

Retrieved on: 
Tuesday, February 28, 2023
Frankfurt Stock Exchange, Economics, Growth, ISIN, ID, Acquisition, Beck, ID Finance, Security (finance), Cryptocurrency

28 th of February 2023 - ID Finance, one of the fastest growing Spanish fintech, has closed 2022 with a record revenue of €170M, showing a 20% annual growth, while net profit grew 17% up to €7.4M.

Key Points: 
  • 28 th of February 2023 - ID Finance, one of the fastest growing Spanish fintech, has closed 2022 with a record revenue of €170M, showing a 20% annual growth, while net profit grew 17% up to €7.4M.
  • The key driver behind the financial performance was Spanish lending platform MoneyMan with a revenue of €119M and a net income of €10.4M.
  • Boris Batine, co-founder of ID Finance said: “I am very proud of the team, which achieved strong growth during the challenging year, whilst maintaining profitability of the business.
  • I am confident we will be able to build upon this success and achieve even stronger results in 2023”.

Schrader Farmer’s Economy Update series enlarged to include four cities

Retrieved on: 
Tuesday, January 31, 2023
Agriculture, Natural Resources, Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Tenants in common 1031 exchange, Beck, Tenant, Country club, Agricultural law, Washburn University School of Law, Salomon, City, Marketing, Risk management, Real estate, Schrader, Auction, Lafayette

Schrader Real Estate and Auction Company will expand its Farmer’s Economy Update series to four cities in 2023, beginning with the first session in Venice, Florida, on February 16.

Key Points: 
  • Schrader Real Estate and Auction Company will expand its Farmer’s Economy Update series to four cities in 2023, beginning with the first session in Venice, Florida, on February 16.
  • The first update will begin at 11:30 a.m. at the Plantation Golf & Country Club in Venice.
  • “The Farmer’s Update series has been well received and attended for several years in Venice and in Fort Wayne, Indiana.
  • We will wrap up the series with our session in Fort Wayne on March 10,” said Schrader.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022
Human voice, Deafness, MT-TL1, Learning, Mitochondrial disease, Cell, Cognition, Enzyme, Clinician, Natural history study, Mitochondrial encephalomyopathy, RAND, Leigh syndrome, Conference, Neuro, Pain, Degenerative disease, Fatigue, Exercise, CFQ, Growth, BDI, DNA, Life, Phase, Lactic acidosis, Global health, Jungian cognitive functions, Diabetes, Research, Severe cognitive impairment, Safety, Gross, Pharmacokinetics, Mutation, Heart failure, Beck, Mitochondrion, Muscle weakness, Government, Point mutation, Collection, Quality of life, Beck Depression Inventory, IIB, Pharmaceutical industry, Medical imaging, Medical device, Patient, MELAS, MIDD

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022
Human voice, Deafness, MT-TL1, Learning, Mitochondrial disease, Cell, Cognition, Enzyme, Clinician, Natural history study, Mitochondrial encephalomyopathy, RAND, Leigh syndrome, Conference, Neuro, Pain, Degenerative disease, Fatigue, Exercise, CFQ, Growth, BDI, DNA, Life, Phase, Lactic acidosis, Global health, Jungian cognitive functions, Diabetes, Research, Severe cognitive impairment, Safety, Gross, Pharmacokinetics, Mutation, Heart failure, Beck, Mitochondrion, Muscle weakness, Government, Point mutation, Collection, Quality of life, Beck Depression Inventory, IIB, Pharmaceutical industry, Medical imaging, Medical device, Patient, MELAS, MIDD

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

Frank Eppink Joins Blue Heron As President, BH Elite Division

Retrieved on: 
Tuesday, September 13, 2022
Emerald, Workflow, Las Vegas (Modern Family), Central Region, Nature, Growth, Blue heron, Industry, Jason Eppink, Environment, Language, Certification, Beck, CEO, National Green Building Standard, Operations management, C.H. Beck, Elite, Solution, Platinum, Purdue University, Founder, Leadership, U.S. Green Building Council, Great blue heron, The Beck Group, Management, Interior design

LAS VEGAS, Sept. 13, 2022 /PRNewswire-PRWeb/ -- Blue Heron, a Las Vegas-based design-led development firm, announced today that esteemed construction industry leader Frank Eppink has joined the company as President of BH Elite, Blue Heron's custom-home division. In this role, he will be responsible for leading the business's continued growth and evolution while ensuring the delivery of unrivaled client satisfaction. Eppink will also serve as a member of Blue Heron's executive leadership team.

Key Points: 
  • LAS VEGAS, Sept. 13, 2022 /PRNewswire-PRWeb/ -- Blue Heron , a Las Vegas-based design-led development firm, announced today that esteemed construction industry leader Frank Eppink has joined the company as President of BH Elite, Blue Heron's custom-home division.
  • "We are delighted to welcome a respected industry professional to Blue Heron and leverage his extensive experience on behalf of our team and our clients," said Tyler Jones, CEO and Founder of Blue Heron.
  • "Frank will provide focused and inspirational leadership for Blue Heron's Elite division and align the team with our business plan, values, and vision."
  • Eppink joins Blue Heron from the Beck Group, Dallas, where he built a distinguished career over 36 years, most recently serving as Regional Director in the Denver office, which he established and led.